



Europese Unie



Europees Fonds voor Regionale Ontwikkeling

COILED

Center for Open Innovation in LEad Discovery


Public private drug discovery platform

OP East NL ERDF – Budget 4.4 M€

Jac Wijkmans, PhD – Inntrest BV

20 June 2018


COILED Consortium Partners



- Combination of unique expertise to translate breakthrough (academic) research into new drug candidates
- **Success:** Building the consortium
- **Issues:** How to include SMEs and how to bridge Dutch regional divide?

R&D Focus: Trained Immunity

Memory-like responses of the innate immune system



- Discovered by 2016 Spinoza-laureate Prof. Mihai Netea (Radboudumc)
- Controlled by specific epigenetic enzymes
- Dysregulated in, e.g.:



CNS disorders



Rheumatoid arthritis




Sepsis




Cancer

Successes

- Starting points generated for selected enzyme targets using different drug discovery approaches
- Optimization of (biological) properties via chemical modification furnished 3 'lead series' – Patent applications are being drafted
- Interest received from pharmaceutical/biotech companies, patient organizations, academic institutions, investors



Structure-based drug design (SBDD)



Ultra high-throughput screening (uHTS)

Note: Official project start: Jul16, First hire: Feb17, Fully resourced: Sep17

Challenges

- To organize the COILED consortium, results & IP in order to be able to valorize COILED and build sustainable platform
Issues: Time, 'Exit' thinking
- To attract additional funds to:
 - Perform drug discovery activities on additional enzyme targets
 - Extend therapeutic focus to, *e.g.*, immuno-oncology and other key therapeutic areas
 - Access very specific specialist know-how and resources